Prostatis Group’s Lowe's Companies LOW Stock Holding History

Prostatis Group’s Portfolio LOW Stock Details LOW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-132,728	Closed	-$136K	–	180
2023 Q2	$136K	Buy	+132,728	New	+$27.6M	0.06%	124
2022 Q1	–	Sell	-999	Closed	-$258K	–	93
2021 Q4	$258K	Buy	999 +11	+1%	+$2.62K	0.16%	86
2021 Q3	$200K	Buy	+988	New	+$197K	0.12%	96

Other funds holding LOW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Prostatis Group's LOW Position: Q3 2023 in Review

Prostatis Group sold out of Lowe's Companies (LOW) in Q3 2023, closing a stake of 132,728 shares — an estimated $136K sold.

Prostatis Group first reported a position in LOW in Q3 2021 and held it in 3 quarters. The position peaked at $258K in Q4 2021. 2,304 funds tracked by Wall St. Rank hold LOW as of Q3 2023.

Prostatis Group reported no remaining Lowe's Companies position as of Q3 2023 after selling out during the quarter.
Prostatis Group sold 132,728 Lowe's Companies shares in Q3 2023, an estimated $136K.
Prostatis Group first reported a position in Lowe's Companies in Q3 2021 and held it in 3 quarters.
Prostatis Group's Lowe's Companies position peaked at $258K in Q4 2021.
2,304 funds tracked by Wall St. Rank held Lowe's Companies as of Q3 2023.

Based on Prostatis Group's 13F filing for Q3 2023, filed 21 Mar 2025.